XORTX Therapeutics Inc. is a biopharmaceutical company with three products in clinical development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-221, under a letter of intent to establish a co-development program with Teijin Pharma Limited, for Type 2 Diabetic Nephropathy (T2DN). The Company has intellectual property rights and established proof of concept through independent clinical studies. XORTX is working to advance its clinical development stage products that target xanthine oxidase to inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future of patients.

Press Releases

XORTX Therapeutics Strengthens Executive Team

Mr. Amar Keshri joins XORTX as Chief Financial Officer July 14, 2021 07:00 ET | Source: XORTX Therapeutics Inc. CALGARY, Alberta, July 14, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive ...
Read More

Receive Press Releases by email

Please enable the javascript to submit this form